*Post-hoc analyses to assess for pharmacodynamic interaction of Velphoro with oral vitamin D analogs. Patients taking cinacalcet/cinacalcet hydrochloride to control iPTH were excluded.1
1. Data on file. Fresenius Medical Care North America, Waltham, MA. 2. Velphoro® [package insert]. Waltham, MA: Fresenius Medical Care North America; 2018. 3. Floege J, Covic AC, Ketteler M, et al; on behalf of the PA21 Study Group. A phase III study of the efficacy and safety of a novel iron-based phosphate binder in dialysis patients. Kidney Int. 2014;86(3):638-647.
Velphoro® (sucroferric oxyhydroxide) is a phosphate binder indicated for the control of serum phosphorus levels in patients with chronic kidney disease on dialysis.
For additional important safety information, please see the full Prescribing Information.
To report SUSPECTED ADVERSE REACTIONS, contact Fresenius Medical Care North America at
1-800-323-5188 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
This information is intended for use by US healthcare professionals only.